“Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma”. SKIN The Journal of Cutaneous Medicine, vol. 2, Dec. 2018, p. S77, https://doi.org/10.25251/skin.2.supp.77.